reduc forecast ebit due weaker expect
perform reduc target price
maintain outperform rate organ growth margin continu
neg impact cyclic issu middl east disrupt
weather north america demand china disrupt
continu longer expect market increasingli concern around
structur problem busi remain outperform stock
given underli strength innov pipelin hygiene/corn led
contribut chri counihan assum primari coverag
still wait return growth leav longer term estim
unchang believ growth medium term support
hygien launch corn inocul uptak share gain
energy/household believ commod price support
growth growth new product pipelin
believ market gain comfort improv
remaind share outperform european
valuat new novozym target price dkr
round averag pe multipl ev/ebitda
dcf reduct target price primarili function
mark market multipl risk outperform thesi lower oil
soft commod price impact longer term growth rate
valuat metric
number share
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
price aug rate outperform target price analyst chri counihan
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
forecast organ growth vs novozym guidanc rang
underli ebit margin exclud defer incom payment
bioag deal chang longer term forecast remain unchang
ebitda upgrad reflect increas depreci impact impair
charg within bioag allianc impact cse adopt run rate ex
impair inclus ifr cse dkr impact
price dkr repres averag dcf ev/ebitda multipl
price-to-earnings multipl valuat methodolog seen
ev/ebitda multipl valuat price-to-earnings multipl valuat seen peer
use includ givaudan christian hansen symris sensient
figur ev/ebitda multipl price-to-earnings multipl valuat
dcf valuat shown
less increase/add decreas wc
free cash-flow firm fcff
cumul factor period
discount factor start first forecast period
share
equiti
debt
averag spread risk-fre rate
pre-tax cost debt
averag corpor tax rate compani
post-tax cost debt
number year explicit estim
year start termin period
highlight month forward consensu ev/ebitda novozym trade
premium peer discount year histor averag month
forward consensu price-to-earnings novozym trade discount peer discount
year histor averag
rel
compani mention price
